Furthermore, analysis of longitudinal PB samples obtained from a cohort of NSCLC patients highlights the potential clinical utility of CX3CR1 as a useful blood-based biomarker to predict response to ICI early after initiation of therapy. The gene discussed is CX3CR1; the disease is non-small cell lung carcinoma.